Cited by 358Obsessive-Compulsive Spectrum DisordersAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychoanalysis and Psychopathology Research

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Augmentation of Behavior Therapy With d -Cycloserine for Obsessive-Compulsive Disorder

Wilhelm, Sabine, Buhlmann, Ulrike, Tolin, David F., Meunier, Suzanne A., Pearlson, Godfrey D., Reese, Hannah E., Cannistraro, Paul, Jenike, Michael A., Rauch, Scott L.·2008·American Journal of Psychiatry

DOI 10.1176/appi.ajp.2007.07050776

Open this paper in CoChat — free account

Abstract

OBJECTIVE: This study examined whether d-cycloserine, a partial agonist at the N-methyl-D-aspartate (NMDA) glutamatergic receptor, enhances the efficacy of behavior therapy for obsessive-compulsive disorder (OCD). METHOD: A randomized, double-blind, placebo-controlled trial investigating D-cycloserine versus placebo augmentation of behavior therapy was conducted in 23 OCD patients. Patients first underwent a diagnostic interview and pretreatment evaluation, followed by a psychoeducational/treatment planning session. Then they received 10 behavior therapy sessions. Treatment sessions were conducted twice per week. One hour before each of the behavior therapy sessions, the participants received either D-cycloserine, 100 mg, or a placebo. RESULTS: Relative to the placebo group, the D-cycloserine group's OCD symptoms were significantly more improved at mid-treatment, and the D-cycloserine group's depressive symptoms were significantly more improved at posttreatment. CONCLUSIONS: These data provide support for the use of D-cycloserine as an augmentation of behavior therapy for OCD and extend findings in animals and other human disorders suggesting that behavior therapy acts by way of long-term potentiation of glutamatergic pathways and that the effects of behavior therapy are potentiated by an NMDA agonist.

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2007.07050776

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,766
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Structured Clinical Interview for DSM-IV Axis I Disorders
Spitzer, R. L., First, M. B., & Gibbon, M. (1997) · Medical Entomology and Zoology · Cited by 3,582
Fear conditioning induces associative long-term potentiation in the amygdala
Rogan, M. T., Stäubli, U. V., & LeDoux, J. E. (1997) · Nature · doi:10.1038/37601 · Cited by 1,310
Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinctionof Fear
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive–compulsive disorder
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048
Why We Think Plasticity Underlying Pavlovian Fear Conditioning Occurs in the Basolateral Amygdala
Fanselow, M. S., & LeDoux, J. E. (1999) · Neuron · doi:10.1016/s0896-6273(00)80775-8 · Cited by 933
Facilitation of Conditioned Fear Extinction by Systemic Administration or Intra-Amygdala Infusions of d-Cycloserine as Assessed with Fear-Potentiated Startle in Rats
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560 · cited 4×
“on social anxiety (14), in our OCD study, the medication was given 1 hour before each session.”
BackgroundMethodInfluential
Treatment of obsessive–compulsive disorder: Cognitive behavior therapy vs. exposure and response prevention
Whittal, M. L., Thordarson, D. S., & McLean, P. D. (2005) · Behaviour Research and Therapy · doi:10.1016/j.brat.2004.11.012 · Cited by 417

Flagged first, then by citations

Show all 30 references

Research works printed but not linked: 4

Cox J, 1994, Q J Exp Psychol B, 47, 187
Kozak MJ, 1997, Tex
First MB, 1995, Patient Edition (SCIDP, version 2.0).
Beck AT, 1996, Steer RA

Sorted by citations

Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
Uncertainty and anticipation in anxiety: an integrated neurobiological and psychological perspective
Grupe, D. W., & Nitschke, J. B. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3524 · Cited by 2,007
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Adding d-cycloserine may hasten the onset of improvements with ERP, with significant benefits over placebo during the first four or five ERP sessions [698-700], but this effect has not been seen in all studies [701].”
Background
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Obsessive-compulsive disorder
Abramowitz, J. S., Taylor, S., & McKay, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60240-3 · Cited by 1,002
Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways
Milad, M. R., & Rauch, S. L. (2012) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.11.003 · Cited by 847
Self-citation
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H., & WFSBP Task Force on Treatment Guide (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 887
Extinction circuits for fear and addiction overlap in prefrontal cortex
Peters, J., Kalivas, P. W., & Quirk, G. J. (2009) · Learning & Memory · doi:10.1101/lm.1041309 · Cited by 736
Understanding how and why psychotherapy leads to change
Kazdin, A. E. (2009) · Psychotherapy Research · doi:10.1080/10503300802448899 · Cited by 728
Fear Extinction and Relapse: State of the Art
Vervliet, B., Craske, M. G., & Hermans, D. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185542 · Cited by 671
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder
Mahan, A. L., & Ressler, K. J. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.06.007 · Cited by 643
Excessive discounting of delayed reinforcers as a trans-disease process contributing to addiction and other disease-related vulnerabilities: Emerging evidence
Bickel, W. K., Jarmolowicz, D. P., Mueller, E. T., Koffarnus, M. N., & Gatchalian, K. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.02.004 · Cited by 604
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510
Self-citation
From Pavlov to PTSD: The extinction of conditioned fear in rodents, humans, and anxiety disorders
VanElzakker, M. B., Kathryn Dahlgren, M., Caroline Davis, F., Dubois, S., & Shin, L. M. (2014) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.11.014 · Cited by 482
How the Neurocircuitry and Genetics of Fear Inhibition May Inform Our Understanding of PTSD
Jovanović, T., & Ressler, K. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09071074 · Cited by 457
Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“(Kushner et al., 2007) OCD 2×/week DCS or placebo 1 h prior 10 ERP sessions 1 month follow-up Re-evaluation of Wilhelm et al., 2008 Faster improvements in DCS group No difference between DCS and placebo group (no further benefit).”
BackgroundMethodInfluential
A Randomized, Double-Blind Evaluation of d -Cycloserine or Alprazolam Combined With Virtual Reality Exposure Therapy for Posttraumatic Stress Disorder in Iraq and Afghanistan War Veterans
Rothbaum, B. O., Price, M., Jovanovic, T., Norrholm, S. D., Gerardi, M., Dunlop, B., Davis, M., Bradley, B., Duncan, E. J., Rizzo, A., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13121625 · Cited by 388
Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD
Greenberg, B. D., Rauch, S. L., & Haber, S. N. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.128 · Cited by 359
Self-citation
The Science of Cognitive Therapy
Hofmann, S. G., Asmundson, G. J. G., & Beck, A. T. (2013) · Behavior Therapy · doi:10.1016/j.beth.2009.01.007 · Cited by 366
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Deficits in Conditioned Fear Extinction in Obsessive-Compulsive Disorder and Neurobiological Changes in the Fear Circuit
Milad, M. R., Furtak, S. C., Greenberg, J. L., Keshaviah, A., Im, J. J., Falkenstein, M. J., Jenike, M., Rauch, S. L., & Wilhelm, S. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.914 · Cited by 308
Self-citation
Cognitive enhancement as a treatment for drug addictions
Sofuoglu, M., DeVito, E. E., Waters, A. J., & Carroll, K. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.021 · Cited by 309
D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data
Mataix-Cols, D., Fernández de la Cruz, L., Monzani, B., Rosenfield, D., Andersson, E., Pérez-Vigil, A., Frumento, P., de Kleine, R. A., Difede, J., Dunlop, B. W., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.3955 · Cited by 288
Self-citation
Fear extinction and BDNF: translating animal models of PTSD to the clinic
Andero, R., & Ressler, K. J. (2012) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2012.00801.x · Cited by 282
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder
Wu, K., Hanna, G. L., Rosenberg, D. R., & Arnold, P. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.007 · Cited by 264
Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder
Otto, M. W., Tolin, D. F., Simon, N. M., Pearlson, G. D., Basden, S., Meunier, S. A., Hofmann, S. G., Eisenmenger, K., Krystal, J. H., & Pollack, M. H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.036 · Cited by 251
Self-citation
The modification of attentional bias to emotional information: A review of the techniques, mechanisms, and relevance to emotional disorders
Browning, M., Holmes, E. A., & Harmer, C. J. (2010) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/cabn.10.1.8 · Cited by 247
Role of inhibition in exposure therapy
Craske, M. G., Liao, B., Brown, L., & Vervliet, B. (2012) · Journal of Experimental Psychopathology · doi:10.5127/jep.026511 · Cited by 237
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
CASALE, A. D., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 243
A Randomized Placebo-Controlled Trial of d-Cycloserine to Enhance Exposure Therapy for Posttraumatic Stress Disorder
de Kleine, R. A., Hendriks, G.-J., Kusters, W. J. C., Broekman, T. G., & van Minnen, A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.033 · Cited by 220
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain
Harvey, R. J., & Yee, B. K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3893 · Cited by 213
Why does depression hurt? Ancestral primary process separation-distress (PANIC/GRIEF) and diminished brain reward (SEEKING) processes in the genesis of depressive affect
Panksepp, J., & Watt, D. (2011) · Psychiatry: Interpersonal and Biological Processes · doi:10.1521/psyc.2011.74.1.5 · Cited by 207
Impaired Extinction Retention in Adolescent Rats: Effects of D-Cycloserine
McCallum, J., Kim, J. H., & Richardson, R. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.92 · Cited by 198
A randomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorder
Litz, B. T., Salters-Pedneault, K., Steenkamp, M. M., Hermos, J. A., Bryant, R. A., Otto, M. W., & Hofmann, S. G. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.05.006 · Cited by 196
A Preliminary Study of D-Cycloserine Augmentation of Cognitive-Behavioral Therapy in Pediatric Obsessive-Compulsive Disorder
Storch, E. A., Murphy, T. K., Goodman, W. K., Geffken, G. R., Lewin, A. B., Henin, A., Micco, J. A., Sprich, S. E., Wilhelm, S., Bengtson, M. A., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.015 · Cited by 193
Self-citation
Prolonged exposure therapy for post-traumatic stress disorder: a review of evidence and dissemination
McLean, C. P., & Foa, E. B. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.94 · Cited by 199
A review of the interplay between tuberculosis and mental health
Doherty, A. M., Kelly, J. R., McDonald, C., O’Dywer, A. M., Keane, J., & Cooney, J. M. (2013) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2013.03.018 · Cited by 187
Glutamate Receptors in Extinction and Extinction-Based Therapies for Psychiatric Illness
Myers, K. M., Carlezon, W. A., & Davis, M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.88 · Cited by 177
Convergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
Animal models of obsessive-compulsive disorder: Exploring pharmacology and neural substrates
Albelda, N., & Joel, D. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.04.006 · Cited by 165
Cognitive enhancement as a pharmacotherapy target for stimulant addiction
Sofuoglu, M. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02791.x · Cited by 159
Dropout rates in exposure with response prevention for obsessive-compulsive disorder: What do the data really say?
Ong, C. W., Clyde, J. W., Bluett, E. J., Levin, M. E., & Twohig, M. P. (2016) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2016.03.006 · Cited by 160
Minority Participation in Randomized Controlled Trials for Obsessive-Compulsive Disorder
Williams, M. T., Powers, M. B., Yun, Y. G., & Foa, E. B. (2009) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2009.11.004 · Cited by 156
Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study
Ghaleiha, A., Entezari, N., Modabbernia, A., Najand, B., Askari, N., Tabrizi, M., Ashrafi, M., Hajiaghaee, R., & Akhondzadeh, S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.015 · Cited by 152
Drug treatment of obsessive-compulsive disorder
Kellner, M. B. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.2/mkellner · Cited by 150
D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia
Smits, J. A. J., Rosenfield, D., Otto, M. W., Powers, M. B., Hofmann, S. G., Telch, M. J., Pollack, M. H., & Tart, C. D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.12.009 · Cited by 142
Neurobiological correlates of cognitions in fear and anxiety: A cognitive-neurobiological information processing model
Hofmann, S. G., Ellard, K. K., & Siegle, G. J. (2012) · Cognition and Emotion · doi:10.1080/02699931.2011.579414 · Cited by 132
Exposure and response prevention for obsessive-compulsive disorder: A review and new directions
Simpson, H., & Hezel, D. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_516_18 · Cited by 161
“Mowrer’s[9] two-factor theory of fear and avoidance provided an influential framework for understanding the etiology of OCD that inspired the development of behavioral treatments for the disorder, including ERP.”
Influential
Remote treatment of obsessive-compulsive disorder: A randomized controlled trial
Wootton, B. M., Dear, B. F., Johnston, L., Terides, M. D., & Titov, N. (2013) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2013.07.002 · Cited by 125
Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder
Ting, J. T., & Feng, G. (2008) · Current Chemical Genomics · doi:10.2174/1875397300802010062 · Cited by 125
d-Cycloserine as an Augmentation Strategy With Cognitive-Behavioral Therapy for Social Anxiety Disorder
Hofmann, S. G., Smits, J. A. J., Rosenfield, D., Simon, N., Otto, M. W., Meuret, A. E., Marques, L., Fang, A., Tart, C., & Pollack, M. H. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12070974 · Cited by 121
Clinical Features, Cognitive Biases, and Treatment of Body Dysmorphic Disorder
Fang, A., & Wilhelm, S. (2015) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032814-112849 · Cited by 127
Self-citation
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: A randomized placebo controlled trial of yohimbine augmentation
Powers, M. B., Smits, J. A. J., Otto, M. W., Sanders, C., & Emmelkamp, P. M. G. (2009) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2009.01.001 · Cited by 122
Evidence-Based Psychological Treatments: An Update and a Way Forward
Barlow, D. H., Bullis, J. R., Comer, J. S., & Ametaj, A. A. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185629 · Cited by 120
NMDA receptors and fear extinction: implications for cognitive behavioral therapy
Davis, M. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/mdavis · Cited by 120
The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia
Labrie, V., & Roder, J. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.08.002 · Cited by 118
D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions
Smits, J. A. J., Rosenfield, D., Otto, M. W., Marques, L., Davis, M. L., Meuret, A. E., Simon, N. M., Pollack, M. H., & Hofmann, S. G. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.06.020 · Cited by 114
“, 2004), and several showing either relatively weak effects (Kushner et al., 2007; Wilhelm et al., 2008), no effects (Guastella et al.”
Background
Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis
Rodrigues, H., Figueira, I., Lopes, A., Gonçalves, R., Mendlowicz, M. V., Coutinho, E. S. F., & Ventura, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093519 · Cited by 109
d -Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants
Andersson, E., Hedman‐Lagerlöf, E., Enander, J., Djurfeldt, D. R., Ljótsson, B., Červenka, S., Isung, J., Svanborg, C., Mataix‐Cols, D., Kaldo, V., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0546 · Cited by 113
How to erase memory traces of pain and fear
Sandkühler, J., & Lee, J. L. C. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.03.004 · Cited by 108
Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d -Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder
Storch, E. A., Wilhelm, S., Sprich, S. E., Henin, A., Micco, J. A., Small, B. J., Mcguire, J. F., Mutch, P. J., Lewin, A. B., Murphy, T. K., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.1128 · Cited by 111
Self-citation
Structural Determinants of d-Cycloserine Efficacy at the NR1/NR2C NMDA Receptors
Dravid, S. M., Burger, P. B., Prakash, A., Geballe, M. T., Yadav, R., Le, P., Vellano, K. M., Snyder, J. P., & Traynelis, S. F. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.5390-09.2010 · Cited by 108
Translating Across Circuits and Genetics Toward Progress in Fear- and Anxiety-Related Disorders
Ressler, K. J. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20010055 · Cited by 104
Need for speed: Evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine
Chasson, G. S., Buhlmann, U., Tolin, D. F., Rao, S. R., Reese, H. E., Rowley, T., Welsh, K. S., & Wilhelm, S. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.03.007 · Cited by 106
Self-citation
BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity
Rakofsky, J. J., Ressler, K. J., & Dunlop, B. W. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.121 · Cited by 112
Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors
Briscione, M. A., Jovanovic, T., & Norrholm, S. D. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00088 · Cited by 105
New Directions in the Cognitive-Behavioral Treatment of OCD: Theory, Research, and Practice
Abramowitz, J. S., Blakey, S. M., Reuman, L., & Buchholz, J. L. (2018) · Behavior Therapy · doi:10.1016/j.beth.2017.09.002 · Cited by 98
The N-Methyl-D-Aspartate Receptor Co-agonist D-Cycloserine Facilitates Declarative Learning and Hippocampal Activity in Humans
Onur, O. A., Schlaepfer, T. E., Kukolja, J., Bauer, A., Jeung, H., Patin, A., Otte, D.-M., Shah, N. J., Maier, W., Kendrick, K. M., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.022 · Cited by 97
Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy
Norrholm, S. D., Jovanović, T., Gerardi, M. A., Breazeale, K. G., Price, M., Davis, M., Duncan, E., Ressler, K. J., Bradley, B., Rizzo, A., et al. (2016) · Behaviour Research and Therapy · doi:10.1016/j.brat.2016.05.002 · Cited by 96
DIFFICULT-TO-TREAT PEDIATRIC OBSESSIVE-COMPULSIVE DISORDER: FEASIBILITY AND PRELIMINARY RESULTS OF A RANDOMIZED PILOT TRIAL OF d -CYCLOSERINE-AUGMENTED BEHAVIOR THERAPY
Farrell, L. J., Waters, A. M., Boschen, M. J., Hattingh, L., McConnell, H. W., Oar, E. L., Collings, N., Zimmer‐Gembeck, M. J., Shelton, D., Ollendick, T. H., et al. (2013) · Depression and Anxiety · doi:10.1002/da.22132 · Cited by 98
Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders
Ori, R., Amos, T., Bergman, H., Soares‐Weiser, K., Ipser, J., & Stein, D. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007803.pub2 · Cited by 104
d-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial
Siegmund, A., Golfels, F., Finck, C., Halisch, A., Räth, D., Plag, J., & Ströhle, A. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.01.020 · Cited by 89
Chronic Antidepressant Treatment Impairs the Acquisition of Fear Extinction
Burghardt, N. S., Sigurdsson, T., Gorman, J. M., McEwen, B. S., & LeDoux, J. E. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.012 · Cited by 94
d-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: A pilot investigation
Ana, E. J. S., Rounsaville, B. J., Frankforter, T. L., Nich, C., Babuscio, T. A., Poling, J. C., Gonsai, K., Hill, K. P., & Carroll, K. M. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.023 · Cited by 88
Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: medication effects, glucocorticoids, and attenuated treatment outcomes.
Otto, M. W., McHugh, R. K., & Kantak, K. M. (2010) · Clinical Psychology Science and Practice · doi:10.1111/j.1468-2850.2010.01198.x · Cited by 87
Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: Focus on pharmacology and preclinical translational models
Harvey, B. H., & Shahid, M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.014 · Cited by 90
Fear Processing, Psychophysiology, and PTSD
Norrholm, S. D., & Jovanović, T. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000189 · Cited by 92
History of Psychosurgery: A Psychiatrist's Perspective
Lapidus, K. A. B., Kopell, B. H., Ben‐Haim, S., Rezai, A. R., & Goodman, W. K. (2013) · World Neurosurgery · doi:10.1016/j.wneu.2013.02.053 · Cited by 87
Effects of intensive cognitive-behavioral therapy on cingulate neurochemistry in obsessive–compulsive disorder
O’Neill, J., Gorbis, E., Feusner, J. D., Yip, J. C., Chang, S. W., Maidment, K. M., Levitt, J. G., Salamon, N., Ringman, J. M., & Saxena, S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.11.010 · Cited by 88
Animal models of obsessive–compulsive disorder: utility and limitations
Alonso, P., López‐Solà, C., Real, E., Segalàs, C., & Menchón, J. M. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s62785 · Cited by 88
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
Exposure and Response Prevention in the Treatment of Obsessive-Compulsive Disorder: Current Perspectives
Law, C., & Boisseau, C. L. (2019) · Psychology Research and Behavior Management · doi:10.2147/prbm.s211117 · Cited by 101
Current animal models of obsessive compulsive disorder: an update
Albelda, N., & Joel, D. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.070 · Cited by 85
Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults
Greenberg, W. M., Benedict, M. M., Doerfer, J., Perrin, M., Panek, L., Cleveland, W. L., & Javitt, D. C. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.10.007 · Cited by 80
D-Cycloserine Facilitation of Fear Extinction and Exposure-Based Therapy Might Rely on Lower-Level, Automatic Mechanisms
Grillon, C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.017 · Cited by 80
“While traditional anxiolytics such as the benzodiazepines or selective serotonin reuptake inhibitors reduce symptom expression, DCS facilitates the effectiveness of EBT (1-5).”
Tau-Mediated NMDA Receptor Impairment Underlies Dysfunction of a Selectively Vulnerable Network in a Mouse Model of Frontotemporal Dementia
Warmus, B. A., Sekar, D. R., McCutchen, E., Schellenberg, G. D., Roberts, R. C., McMahon, L. L., & Roberson, E. D. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.3418-14.2014 · Cited by 82
Critical brain circuits at the intersection between stress and learning
Bangasser, D. A., & Shors, T. J. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.02.002 · Cited by 78
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.
Krystal, J. H., Tolin, D. F., Sanacora, G., Castner, S. A., Williams, G. V., Aikins, D. E., Hoffman, R. E., & D'Souza, D. C. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.002 · Cited by 76
Self-citation
d-Cycloserine Augmentation of Cognitive Behavioral Therapy for Anxiety Disorders: an Update
Hofmann, S. G., Otto, M. W., Pollack, M. H., & Smits, J. A. J. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0532-2 · Cited by 76
A Trial of D-Cycloserine to Treat Stereotypies in Older Adolescents and Young Adults With Autism Spectrum Disorder
Urbano, M. R., Okwara, L., Manser, P., Hartmann, K., Herndon, A. L., & Deutsch, S. I. (2014) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000033 · Cited by 75
Augmentation of exposure therapy with post-session administration of D-cycloserine
Tart, C. D., Handelsman, P. R., DeBoer, L. B., Rosenfield, D., Pollack, M. H., Hofmann, S. G., Powers, M. B., Otto, M. W., & Smits, J. A. J. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.024 · Cited by 75
Effects of Post-Session Administration of Methylene Blue on Fear Extinction and Contextual Memory in Adults With Claustrophobia
Telch, M. J., Bruchey, A. K., Rosenfield, D., Cobb, A. R., Smits, J. A. J., Pahl, S. A., & Gonzalez-Lima, F. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101407 · Cited by 77
Glutamatergic modulatory therapy for Tourette syndrome
Singer, H. S., Morris, C. M., & Grados, M. A. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.11.028 · Cited by 74
Testing the effects of Δ9-THC and D-cycloserine on extinction of conditioned fear in humans
Klumpers, F., Denys, D., Kenemans, J. L., Grillon, C., van der Aart, J., & Baas, J. M. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431624 · Cited by 72
D-Cycloserine Effects on Extinction of Conditioned Responses to Drug-Related Cues
Myers, K. M., & Carlezon, W. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.030 · Cited by 72
Behavioral changes in G72/G30 transgenic mice
Otte, D. M., Bilkei‐Gorzó, A., Filiou, M. D., Turck, C. W., Yilmaz, Ö., Holst, M. I., Schilling, K., Jamra, R. A., Schumacher, J., Benzel, I. M., et al. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.12.009 · Cited by 72
Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives
Karthik, S., Sharma, L. P., & Narayanaswamy, J. C. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s211703 · Cited by 78

Authors: Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., Cannistraro, P., Jenike, M. A., & Rauch, S. L.
Affiliations: Harvard University (US)
ORCID: Wilhelm, Sabine
Buhlmann, Ulrike
Tolin, David F.
Pearlson, Godfrey D.
Reese, Hannah E.
Jenike, Michael A.
Rauch, Scott L.
Venue: American Journal of Psychiatry
Publisher: American Psychiatric Association Publishing
Published: 2008-03
Volume: 165
Issue: 3
Pages: 335-341
ISSN: 0002-953X (ISSN-L)
1535-7228
DOI: 10.1176/appi.ajp.2007.07050776
OpenAlex: W2038335379
Semantic Scholar: d1309dc52689e30eae911778d6e9c8b6cc61a87f
Cited by: 358
References: 30
Citations by year: 2026: 2 · 2025: 1 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 11 · 2018: 16 · 2017: 24 · 2016: 13 · 2015: 24 · 2014: 36 · 2013: 33 · 2012: 41
FWCI: 48.90
Type: journal article
Language: en
Open access: closed
Locations: American Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
Keywords: D-cycloserine, obsessive-compulsive disorder, behavior therapy, augmentation therapy, NMDA receptor partial agonist, glutamatergic pathways, long-term potentiation, depressive symptoms
MeSH terms: Adult, Animals, Behavior Therapy, Combined Modality Therapy, Cycloserine, Double-Blind Method, Female, Follow-Up Studies, Humans, Implosive Therapy, Obsessive-Compulsive Disorder, Placebos, Psychiatric Status Rating Scales, Severity of Illness Index, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders, Rats, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Augmentation of Behavior Therapy With d -Cycloserine for Obsessive-Compulsive Disorder

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks